Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

D'Amico Risk Classification

The D'Amico classification system stratifies patients with localized prostate cancer into three risk groups (Low, Intermediate, High) based on PSA, Gleason Score, and Clinical Stage.

Evidence-based context for fast calculator use

Purpose:
D'Amico classification stratifies localized prostate cancer into Low, Intermediate, or High risk using PSA, Gleason, and stage to guide treatment.
Population:
patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment
Factors:
PSA Level, Gleason Score, Clinical Stage
Reference:
D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974.
HomeD'Amico Risk Classification
Pin your most used calculators here by clicking the star in the dropdown.

D'Amico Risk Classification

Clinical Context & Background

The D'Amico classification system stratifies patients with localized prostate cancer into three risk groups (Low, Intermediate, High) based on PSA, Gleason Score, and Clinical Stage. It predicts the risk of biochemical recurrence after localized treatment.
Primary Source EvidenceD'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974.
Formula Logic
Risk group determined by the worst feature present.

Reference Data

Risk GroupDefinition5-Year PSA Failure Risk
Low RiskPSA ≤10 AND Gleason ≤6 AND T1-T2a< 10-20%
Intermediate RiskPSA 10-20 OR Gleason 7 OR T2b20-40%
High RiskPSA >20 OR Gleason ≥8 OR ≥T2c> 50%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use D'Amico Risk Classification when d'Amico classification stratifies localized prostate cancer into Low, Intermediate, or High risk using PSA, Gleason, and stage to guide treatment.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm biopsy versus prostatectomy setting, PSA timing, grade group, clinical/pathologic stage, imaging, life expectancy, and treatment history.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Diagnostic, post-prostatectomy, genomic, and recurrence tools must be used only at their intended decision point.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment

How to apply this result

For a representative case, verify PSA Level, Gleason Score, Clinical Stage, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Prostate Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

Epstein Criteria (Insignificant Cancer)PI-RADS™ v2.1 (Prostate MRI)Gleason Score & ISUP Grade

Frequently Asked Questions

When should D'Amico Risk Classification be used?

Use it for patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment when all required inputs and the intended clinical setting are confirmed.

Can D'Amico Risk Classification determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.